Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analyses

被引：9

作者：

Palassini, E. ^{[1
]}

Mir, O. ^{[2
]}

Grignani, G. ^{[3
]}

Vincenzi, B. ^{[4
]}

Gelderblom, H. ^{[5
]}

Sebio, A. ^{[6
]}

Valverde, C. ^{[7
]}

Baldi, G. G. ^{[8
]}

Brunello, A. ^{[9
]}

Cardellino, G. G. ^{[10
]}

Marrari, A. ^{[11
]}

Badalamenti, G. ^{[12
]}

Martin-Broto, J. ^{[13
]}

Ferraresi, V ^{[14
]}

Libertini, M. ^{[15
]}

Turano, S. ^{[16
]}

Gataa, I ^{[17
]}

Collini, P. ^{[18
]}

Dei Tos, A. P. ^{[19
]}

Gennaro, M. ^{[1
]}

Bini, F. ^{[1
]}

Provenzano, S. ^{[2
]}

Lo Vullo, S. ^{[20
]}

Mariani, L. ^{[20
]}

Le Cesne, A. ^{[2
]}

Casali, P. G. ^{[1
]}

机构：

[1] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

[2] Gustave Roussy, Sarcoma Grp, Dept Ambulatory Canc Care, Villejuif, France

[3] FPO IRCCS, Div Med Oncol, Candiolo Canc Inst, Candiolo, TO, Italy

[4] Campus Biomed Univ, Dept Med Oncol, Rome, Italy

[5] LUMC Leiden Univ Med Ctr, Dept Med Oncol, Leiden, Netherlands

[6] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain

[7] Vall dHebron Univ Hosp, Barcelona, Spain

[8] Osped Santo Stefano, Dept Med Oncol, Prato, Italy

[9] IRCCS, Dept Oncol, Ist Oncol Veneto IOV, Oncol Unit 1, Padua, Italy

[10] Azienda Sanitaria Univ Friuli Cent, Dept Oncol, Presidio S Maria della Misericordia Udine, Udine, Italy

[11] Humanitas Canc Ctr Rozzano, Dept Oncol & Hematol, Milan, Italy

[12] Univ Palermo, Dept Surg Oncol & Oral Sci, Sect Med Oncol, Palermo, Italy

[13] Fdn Jimenez Diaz Univ Hosp, Madrid, Spain

[14] IRCCS Regina Elena Natl Canc Inst, Sarcomas & Rare Tumors Unit, Rome, Italy

[15] Fdn Poliambulanza, Dept Oncol, Brescia, Italy

[16] Azienda Osped Cosenza, Dept Oncol, Cosenza, Italy

[17] Fdn IRCCS Ist Nazl Tumori, Dept Pathol, Milan, Italy

[18] Azienda Osped Univ Padova, Dept Pathol, Padua, Italy

[19] Fdn IRCCS Ist Nazl Tumori, Dept Surg, Milan, Italy

[20] Fdn IRCCS Ist Nazl Tumori, Unit Clin Epidemiol & Trial Org, Milan, Italy

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2022年 / 192卷 / 03期

关键词：

Breast tumor; Phyllodes; Sarcoma; Chemotherapy; Advanced setting; SOFT-TISSUE; DIAGNOSIS;

D O I：

10.1007/s10549-022-06524-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background We aimed at investigating outcome of systemic treatments in advanced breast PT. Methods All cases of advanced breast PT treated with systemic treatments from 1999 to 2019, in one of the referral sarcoma centers involved in the study, were retrospectively reviewed. Results 56 female patients were identified. Median age was 52 (range of 25-76) years. Patients received a median number of 2 systemic treatments (range of 1-4). Best responses according to RECIST were 1 (3.7%) CR, 11 (40.7%) PR, 6 (22.2%) SD, 9 (33.3%) PD with anthracyclines plus ifosfamide (AI); 2 (16.7%) PR, 4 (33.3%) SD, 6 (50.0%) PD with anthracycline alone; 3 (18.8%) PR, 4 (25.0%) SD, 9 (56.3%) PD with high-dose ifosfamide given as a continuous infusion (HD-IFX); 3 (20.0%) SD, 12 (80.0%) PD with a gemcitabine-based regimen (with 2 patients not evaluable); 1 (8.3%) PR, 2 (16.7%) SD, 9 (75.0%) PD with trabectedin (with 1 patient not evaluable); 1 (16.7%) PR, 1 (16.7%) SD, 4 (66.7%) PD with tyrosine-kinase inhibitors (TKI). The median PFS were 5.7 (IQR 2.5-9.1) months with AI; 3.2 (IQR 2.2-5.0) months with anthracycline alone; 3.4 (IQR 1.4-6.7) months with HD-IFX; 2.1 (IQR 1.4-5.2) months with gemcitabine-based chemotherapy; 1.8 (IQR 0.7-6.6) months with trabectedin; 3.4 (IQR 3.1-3.8) months with TKI. With a median follow-up of 35.3 (IQR 17.6-66.9) months, OS from the start of first-line systemic treatment was 15.2 (IQR 7.6-39.6) months. Conclusion In this series of advanced PT (to our knowledge, the largest reported so far), AI was associated with a high rate of responses, however, with a median PFS of 5.7 months. Other systemic treatments were poorly active.

引用

页码：603 / 610

页数：8

共 18 条

[1] Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors [J].

Cani, Andi K. ;

Hovelson, Daniel H. ;

McDaniel, Andrew S. ;

Sadis, Seth ;

Haller, Michaela J. ;

Yadati, Venkata ;

Amin, Anmol M. ;

Bratley, Jarred ;

Bandla, Santhoshi ;

Williams, Paul D. ;

Rhodes, Kate ;

Liu, Chia-Jen ;

Quist, Michael J. ;

Rhodes, Daniel R. ;

Grasso, Catherine S. ;

Kleer, Celina G. ;

Tomlins, Scott A. .

MOLECULAR CANCER RESEARCH, 2015, 13 (04) :613-619

[2] Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 29, pg 51, 2018) [J].

Casali, P. G. ;

Abecassis, N. ;

Aro, H. T. ;

Bauer, S. ;

Biagini, R. ;

Bielack, S. ;

Bonvalot, S. ;

Boukovinas, I. ;

Bovee, J. V. M. G. ;

Brodovvicz, T. ;

Broto, J. M. ;

Buonadonna, A. ;

De Alava, E. ;

Tos, A. P. Dei ;

Del Muro, X. G. ;

Dileo, P. ;

Eriksson, M. ;

Fedenko, A. ;

Ferraresi, V. ;

Ferrari, A. ;

Ferrari, S. ;

Frezza, A. M. ;

Gasperoni, S. ;

Gelderblom, H. ;

Gil, T. ;

Grignani, G. ;

Gronchi, A. ;

Haas, R. L. ;

Hassan, B. ;

Hohenberger, P. ;

Lssels, R. ;

Joensuu, H. ;

Jones, R. L. ;

Judson, I. ;

Jutte, P. ;

Kaal, S. ;

Kasper, B. ;

Kopeckova, K. ;

Krakorova, D. A. ;

Le Cesne, A. ;

Lugowska, I. ;

Merimsky, O. ;

Montemurro, M. ;

Pantaleo, M. A. ;

Piana, R. ;

Picci, P. ;

Piperno-Neumann, S. ;

Pousa, A. L. ;

Reichardt, P. ;

Robinson, M. H. .

ANNALS OF ONCOLOGY, 2018, 29 :268-269

[3] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[4] Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group [J].

Grignani, Giovanni ;

D'Ambrosio, Lorenzo ;

Pignochino, Ymera ;

Palmerini, Emanuel ;

Zucchetti, Massimo ;

Boccone, Paola ;

Aliberti, Sandra ;

Stacchiotti, Silvia ;

Bertulli, Rossella ;

Piana, Raimondo ;

Miano, Sara ;

Toloineo, Francesco ;

Chiabotto, Giulia ;

Sangiolo, Dario ;

Pisacane, Alberto ;

Dei Tos, Angelo Paolo ;

Novara, Luca ;

Bartolini, Alice ;

Marchesi, Emanuela ;

D'Incaici, Maurizio ;

Bardelli, Alberto ;

Picci, Piero ;

Ferrari, Stefano ;

Aglietta, Massimo .

LANCET ONCOLOGY, 2018, 19 (10) :1360-1371

[5] Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial [J].

Judson, Ian ;

Verweij, Jaap ;

Gelderblom, Hans ;

Hartmann, Jorg T. ;

Schoeffski, Patrick ;

Blay, Jean-Yves ;

Kerst, J. Martijn ;

Sufliarsky, Josef ;

Whelan, Jeremy ;

Hohenberger, Peter ;

Krarup-Hansen, Anders ;

Alcindor, Thierry ;

Marreaud, Sandrine ;

Litiere, Saskia ;

Hermans, Catherine ;

Fisher, Cyril ;

Hogendoorn, Pancras C. W. ;

dei Tos, A. Paolo ;

van der Graaf, Winette T. A. .

LANCET ONCOLOGY, 2014, 15 (04) :415-423

[6] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].

KAPLAN, EL ;

MEIER, P .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481

[7] Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity [J].

Liu, Su-Yang ;

Joseph, Nancy M. ;

Ravindranathan, Ajay ;

Stohr, Bradley A. ;

Greenland, Nancy Y. ;

Vohra, Poonam ;

Hosfield, Elizabeth ;

Yeh, Iwei ;

Talevichl, Eric ;

Onoderal, Courtney ;

Van Ziffle, Jessica A. ;

Grenert, James P. ;

Bastian, Boris C. ;

Chen, Yunn-Yi ;

Krings, Gregor .

MODERN PATHOLOGY, 2016, 29 (09) :1012-1027

[8] Treatment of Patients with Distant Metastases from Phyllodes Tumor of the Breast [J].

Mitus, J. W. ;

Blecharz, P. ;

Walasek, T. ;

Reinfuss, M. ;

Jakubowicz, J. ;

Kulpa, J. .

WORLD JOURNAL OF SURGERY, 2016, 40 (02) :323-328

[9] Impact of Metastasis Surgery and Alkylating-Agent-Based Chemotherapy on Outcomes of Metastatic Malignant Phyllodes Tumors: A Multicenter Retrospective Study [J].

Neron, Mathias ;

Sajous, Christophe ;

Thezenas, Simon ;

Piperno-Neumann, Sophie ;

Reyal, Fabien ;

Lae, Marick ;

Chakiba, Camille ;

Penel, Nicolas ;

Ryckewaert, Thomas ;

Honore, Charles ;

Bertucci, Francois ;

Monneur, Audrey ;

Salas, Sebastien ;

Duffaud, Florence ;

Saada-Bouzid, Esma ;

Isambert, Nicolas ;

Brahmi, Mehdi ;

Ray-Coquard, Isabelle ;

Blay, Jean-Yves ;

Firmin, Nelly .

ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (05) :1693-1699

[10] Comprehensive genomic profiling of malignant phyllodes tumors of the breast [J].

Nozad, Sahar ;

Sheehan, Christine E. ;

Gay, Laurie M. ;

Elvin, Julia A. ;

Vergilio, Jo-Anne ;

Suh, James ;

Ramkissoon, Shakti ;

Schrock, Alexa B. ;

Hirshfield, Kim M. ;

Ali, Nadia ;

Ganesan, Shridar ;

Ali, Siraj M. ;

Miller, Vincent A. ;

Stephens, Philip J. ;

Ross, Jeffrey S. ;

Chung, Jon H. .

BREAST CANCER RESEARCH AND TREATMENT, 2017, 162 (03) :597-602

← 1 2 →